In the Spotlight: BioVie's (NASDAQ: BIVI) Quest to Tackle Alzheimer's, Parkinson's, and More

BioVie is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) and BIV201 for Refractory Ascites and HRS-AKI. Visit https://bit.ly/BioVie to learn more.